Lisa Takagi

Japan

Managing Editor, Japan at The Pink Sheet

Managing Editor, Japan at Scrip

Featured in: Favicon

informa.com (+4) Favicon

signalhfx.ca Favicon

itmedia.co.jp Favicon

citeline.com (+1)

Articles

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

1 week ago | insights.citeline.com | Joseph Haas |Lisa Takagi |Sushmita Panda |Xu Hu

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADCAxcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.
Welireg Among Japan Recommendations; Economic Policy Raises Hopes Of Higher Prices

1 week ago | insights.citeline.com | Lisa Takagi

Welireg Among Japan Recommendations; Economic Policy Raises Hopes Of Higher PricesIndustry Reacts PositivelyCountry recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.
Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

2 weeks ago | insights.citeline.com | Joseph Haas |Lisa Takagi |Vibha Ravi |Sushmita Panda

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To BenzPlus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.
Citeline Japan Awards 2025 - Enter Now!

2 weeks ago | insights.citeline.com | Ian Haydock |Lisa Takagi

Citeline Japan Awards 2025 - Enter Now!14 July Deadline The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available. 14 July deadline for entries for the Citeline Japan Awards 2025 • Source: Citeline
Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

2 weeks ago | insights.citeline.com | Lisa Takagi

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home. (Shutterstock/AI-generated)
Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

2 weeks ago | insights.citeline.com | Lisa Takagi

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For ReformsWhile the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home. (Shutterstock/AI-generated)
Japan Price Cuts For Epkinly and Lunsumio Following CEA

1 month ago | insights.citeline.com | Lisa Takagi

Japan Price Cuts For Epkinly and Lunsumio Following CEAWegovy, Leqembi And Others In SpotlightJapan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi. Japan cuts prices, looks at products under cost effectiveness scheme (Shutterstock/AI-generated)
Japan Reimburses 11 New Drugs But Slashes Price Of Others By Up To 20%

1 month ago | insights.citeline.com | Lisa Takagi

Japan Reimburses 11 New Drugs But Slashes Price Of Others By Up To 20%Give And Take Under NHI Scheme Japan's NHI program continues to give and take as 11 new drugs are granted reimbursement, while the prices of others - including three ophthalmic therapies - are cut by up to 20% under a Market Expansion Repricing scheme. Japan balances health costs as it reimburses a batch a new drugs while cutting prices of other fast-expanding therapies. (Shutterstock/AI-generated)
Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

1 month ago | insights.citeline.com | Lisa Takagi

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear Major Firms Report Fiscal Year Results Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth. US a key driver of major Japanese pharma companies' growth last fiscal year. (Shutterstock/AI-generated)
Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

1 month ago | insights.citeline.com | Joseph Haas |Xu Hu |Anju Ghangurde |Lisa Takagi

Asia Deal Watch: Lilly Partners With Rznomics On Hearing LossPlus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.